Mylan plans to close a manufacturing plant in Decatur, Illinois that it gained as part of its $7.2-billion acquisition of Meda Aktiebolag, a Solna, Sweden-headquartered pharmaceutical company, in August 2016.

The Decatur plant, which has approximately 90 employees, produces a variety of products, including the pain medication, Soma (carisoprodol), and the multivitamin, Geritol. Operations at the plant will continue over several months, with staff reductions taking place in phases. Final closure is expected to be completed in 2018. The products manufactured in Decatur will continue to be manufactured in the US.

In a company statement, Mylan said: “Since 2015, Mylan has made a number of significant acquisitions, and as part of the holistic, global integration of these acquisitions, we announced in December 2016 that it would be focusing on how to best optimize and maximize all of our assets across the organization and across all geographies. Last month, we announced plans to close our Decatur, Ill., facility, which we acquired as part of our Meda transaction in 2016. This closure is part of the integration process announced in December of last year. The decision to close the site comes after a careful assessment of bringing the two businesses together as part of our integration process and is consistent with our ongoing efforts to operate our businesses as efficiently as possible.”

With the acquisition of Meda, Mylan gained six manufacturing plants. In addition to the Decatur plant, Mylan gained manufacturing facilities in Dublin, Ireland; Troisdorf and Cologne, Germany; Confienza, Italy; and Merignac, France.

Source: Mylan